MovDisordV3, PubMed, Curation, bibRecord, 002F30

Toward future therapies in progressive supranuclear palsy.

Identifieur interne : 002F30 ( PubMed/Curation ); précédent : 002F29; suivant : 002F31

Toward future therapies in progressive supranuclear palsy.

Auteurs : David J. Burn [Royaume-Uni] ; Naomi M. Warren

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2005.

RBID : pubmed:16092097

English descriptors

KwdEn :
- Adrenergic Agents (therapeutic use), Anti-Dyskinesia Agents (therapeutic use), Cholinergic Agents (therapeutic use), Dopamine Agents (therapeutic use), Humans, Neurotransmitter Agents (therapeutic use), Palliative Care, Supranuclear Palsy, Progressive (drug therapy), Supranuclear Palsy, Progressive (therapy).
MESH :
- chemical , therapeutic use : Adrenergic Agents, Anti-Dyskinesia Agents, Cholinergic Agents, Dopamine Agents, Neurotransmitter Agents.
- drug therapy : Supranuclear Palsy, Progressive.
- therapy : Supranuclear Palsy, Progressive.
- Humans, Palliative Care.

Abstract

There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies.

DOI: 10.1002/mds.20546
PubMed: 16092097

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002F30

Links to Exploration step

pubmed:16092097

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toward future therapies in progressive supranuclear palsy.</title>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J" last="Burn">David J. Burn</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne, UK. d.j.burn@ncl.ac.uk</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M" last="Warren">Naomi M. Warren</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="doi">10.1002/mds.20546</idno>
<idno type="RBID">pubmed:16092097</idno>
<idno type="pmid">16092097</idno>
<idno type="wicri:Area/PubMed/Corpus">002F30</idno>
<idno type="wicri:Area/PubMed/Curation">002F30</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Toward future therapies in progressive supranuclear palsy.</title>
<author><name sortKey="Burn, David J" sort="Burn, David J" uniqKey="Burn D" first="David J" last="Burn">David J. Burn</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne, UK. d.j.burn@ncl.ac.uk</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Warren, Naomi M" sort="Warren, Naomi M" uniqKey="Warren N" first="Naomi M" last="Warren">Naomi M. Warren</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Agents (therapeutic use)</term>
<term>Anti-Dyskinesia Agents (therapeutic use)</term>
<term>Cholinergic Agents (therapeutic use)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Humans</term>
<term>Neurotransmitter Agents (therapeutic use)</term>
<term>Palliative Care</term>
<term>Supranuclear Palsy, Progressive (drug therapy)</term>
<term>Supranuclear Palsy, Progressive (therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenergic Agents</term>
<term>Anti-Dyskinesia Agents</term>
<term>Cholinergic Agents</term>
<term>Dopamine Agents</term>
<term>Neurotransmitter Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Supranuclear Palsy, Progressive</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Humans</term>
<term>Palliative Care</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies.</div>
</front>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">16092097</PMID>
<DateCreated><Year>2005</Year>
<Month>08</Month>
<Day>15</Day>
</DateCreated>
<DateCompleted><Year>2005</Year>
<Month>12</Month>
<Day>13</Day>
</DateCompleted>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>20 Suppl 12</Volume>
<PubDate><Year>2005</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>Toward future therapies in progressive supranuclear palsy.</ArticleTitle>
<Pagination><MedlinePgn>S92-8</MedlinePgn>
</Pagination>
<Abstract><AbstractText>There is a stern therapeutic challenge for progressive supranuclear palsy (PSP) that has not yet been met. The lack of randomized, controlled trials and negative outcomes from the vast majority of studies make it impossible to set therapeutic standards, or to give clear recommendations. We review progress to date in this area and briefly consider future potential therapeutic strategies.</AbstractText>
<CopyrightInformation>Copyright 2005 Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Burn</LastName>
<ForeName>David J</ForeName>
<Initials>DJ</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Regional Neurosciences Centre, Newcastle General Hospital and Institute for Ageing and Health, University of Newcastle upon Tyne, UK. d.j.burn@ncl.ac.uk</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Warren</LastName>
<ForeName>Naomi M</ForeName>
<Initials>NM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018663">Adrenergic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018726">Anti-Dyskinesia Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018678">Cholinergic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D018663">Adrenergic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018726">Anti-Dyskinesia Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018678">Cholinergic Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018377">Neurotransmitter Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D010166">Palliative Care</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D013494">Supranuclear Palsy, Progressive</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000188">drug therapy</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000628">therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<NumberOfReferences>71</NumberOfReferences>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>8</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>12</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>8</Month>
<Day>11</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="doi">10.1002/mds.20546</ArticleId>
<ArticleId IdType="pubmed">16092097</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F30 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002F30 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:16092097
   |texte=   Toward future therapies in progressive supranuclear palsy.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:16092097" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Toward future therapies in progressive supranuclear palsy.

Toward future therapies in progressive supranuclear palsy.

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki